Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Stoke Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Stoke Therapeutics, Inc.

STOK

Stoke Therapeutics, Inc.

About Stoke Therapeutics, Inc.

Stoke Therapeutics is a late-stage biotech company developing RNA-based medicines using its proprietary TANGO platform to upregulate protein expression. Focused on severe genetic diseases like Dravet syndrome and ADOA, it designs antisense oligonucleotides to restore normal protein levels, addressing underlying causes. The company collaborates globally for development and commercialization, aiming to deliver disease-modifying therapies for central nervous system and eye disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Stoke Therapeutics, Inc.

1
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports Revenue Decline to $6.2 Million and $50 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports $184.4M Revenue for Fiscal Year 2025, Increases R&D Investments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports $10.6M Revenue in Q3 2025, Net Loss of $38.3M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports $13.8M Revenue and $23.5M Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports $158.6 Million Revenue and $112.9 Million Net Income in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports $36.6M Revenue Growth and Plans Phase 3 Study for Zorevunersen

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Stoke Therapeutics, Inc. Stoke Therapeutics Reports 24% Revenue Growth, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments